Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 7/20 | 0.53 |
| ▸ | FLT3 | P36888 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268718 | 1.00 | SLC34A2 (0.53) | SLC34A2FLT3MEN1KMT2AMAPT | |
| SCHEMBL267587 | 0.98 | SLC34A2 (0.51) | SLC34A2FLT3MEN1KMT2AMAPT | |
| SCHEMBL267586 | 0.98 | SLC34A2 (0.51) | SLC34A2FLT3MEN1KMT2AMAPT | |
| SCHEMBL267215 | 0.93 | SLC34A2 (0.52) | SLC34A2FLT3MEN1KMT2AMAPT | |
| SCHEMBL273826 | 0.93 | SLC34A2 (0.52) | SLC34A2FLT3MEN1KMT2AMAPT | |
| SCHEMBL267495 | 0.92 | SLC34A2 (0.50) | SLC34A2FLT3MEN1KMT2AMAPT | |
| SCHEMBL267494 | 0.92 | SLC34A2 (0.50) | SLC34A2FLT3MEN1KMT2AMAPT | |
| SCHEMBL265629 | 0.91 | SLC34A2 (0.53) | SLC34A2FLT3MEN1KMT2AMAPT | |
| SCHEMBL265630 | 0.91 | SLC34A2 (0.53) | SLC34A2FLT3MEN1KMT2AMAPT | |
| SCHEMBL268955 | 0.91 | SLC34A2 (0.52) | SLC34A2FLT3MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | SLC34A1, SLC34A2, SLC20A2 | SLC34A2 2/4885FLT3 2535/4885MEN1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.